British pharmaceutical giant GSK has not met required ethical and regulatory standards in the marketing and prescription ...

GSK is paying to access ABL Bio’s Grabody-B platform, which potentially enables therapies to cross the blood-brain barrier.

The reversal from the Advisory Committee on Immunization Practices (ACIP) is a potential boost for GSK and Pfizer. Both companies saw sales of their RSV vaccines for adults tumble last year after ...

The pharma giant is wagering potentially billions of dollars on technology from ABL Bio that’s designed to get drugs across the blood-brain barrier.

Bearish flow noted in GSK (GSK) Pharma with 6,103 puts trading, or 5x expected. Most active are 3/14 weekly 39.5 puts and Mar-25 41.5 calls, with total volume in those strikes near 5,500 contracts.

LONDON, March 25 (Reuters) - GSK (GSK.L), opens new tab said on ... Maggie is a Britain-based reporter covering the European pharmaceuticals industry with a global perspective.

The UK’s National Institute for Health and Care Excellence (NICE) has recommended GlaxoSmithKline’s (GSK) ZEJULA (niraparib) for some forms of ovarian, fallopian tube, and peritoneal cancer.

A special congressional committee has recommended a $15 billion investment to boost the United States' biotech advantage over ...

GlaxoSmithKline (GSK) is set to apply artificial intelligence (AI) technology to improve its drug discovery efforts through a collaboration with Cloud Pharmaceuticals. Its deal with the US-based ...